PIM kinase (and Akt) biology and signaling in tumors

Noel A. Warfel, Andrew Kraft

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

The initiation and progression of human cancer is frequently linked to the uncontrolled activation of survival kinases. Two such pro-survival kinases that are commonly amplified in cancer are PIM and Akt. These oncogenic proteins are serine/threonine kinases that regulate tumorigenesis by phosphorylating substrates that control the cell cycle, cellular metabolism, proliferation, and survival. Growing evidence suggests that cross-talk exists between the PIM and Akt kinases, indicating that they control partially overlapping survival signaling pathways that are critical to the initiation, progression, and metastatic spread of many types of cancer. The PI3K/Akt signaling pathway is activated in many human tumors, and it is well established as a promising anticancer target. Likewise, based on the role of PIM kinases in normal and tumor tissues, it is clear that this family of kinases represents an interesting target for anticancer therapy. Pharmacological inhibition of PIM has the potential to significantly influence the efficacy of standard and targeted therapies. This review focuses on the regulation of PIM kinases, their role in tumorigenesis, and the biological impact of their interaction with the Akt signaling pathway on the efficacy of cancer therapy.

Original languageEnglish (US)
Pages (from-to)41-49
Number of pages9
JournalPharmacology and Therapeutics
Volume151
DOIs
StatePublished - May 30 2015

Fingerprint

Phosphotransferases
Neoplasms
Carcinogenesis
Critical Pathways
Survival
Protein-Serine-Threonine Kinases
Cell Cycle Checkpoints
Phosphatidylinositol 3-Kinases
Therapeutics
Cell Proliferation
Pharmacology

Keywords

  • Akt
  • Cancer
  • Oncogenes
  • PIM kinases
  • Therapeutic resistance

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

PIM kinase (and Akt) biology and signaling in tumors. / Warfel, Noel A.; Kraft, Andrew.

In: Pharmacology and Therapeutics, Vol. 151, 30.05.2015, p. 41-49.

Research output: Contribution to journalArticle

@article{4cb6d7163f224486bafa0e7ff11b30c2,
title = "PIM kinase (and Akt) biology and signaling in tumors",
abstract = "The initiation and progression of human cancer is frequently linked to the uncontrolled activation of survival kinases. Two such pro-survival kinases that are commonly amplified in cancer are PIM and Akt. These oncogenic proteins are serine/threonine kinases that regulate tumorigenesis by phosphorylating substrates that control the cell cycle, cellular metabolism, proliferation, and survival. Growing evidence suggests that cross-talk exists between the PIM and Akt kinases, indicating that they control partially overlapping survival signaling pathways that are critical to the initiation, progression, and metastatic spread of many types of cancer. The PI3K/Akt signaling pathway is activated in many human tumors, and it is well established as a promising anticancer target. Likewise, based on the role of PIM kinases in normal and tumor tissues, it is clear that this family of kinases represents an interesting target for anticancer therapy. Pharmacological inhibition of PIM has the potential to significantly influence the efficacy of standard and targeted therapies. This review focuses on the regulation of PIM kinases, their role in tumorigenesis, and the biological impact of their interaction with the Akt signaling pathway on the efficacy of cancer therapy.",
keywords = "Akt, Cancer, Oncogenes, PIM kinases, Therapeutic resistance",
author = "Warfel, {Noel A.} and Andrew Kraft",
year = "2015",
month = "5",
day = "30",
doi = "10.1016/j.pharmthera.2015.03.001",
language = "English (US)",
volume = "151",
pages = "41--49",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - PIM kinase (and Akt) biology and signaling in tumors

AU - Warfel, Noel A.

AU - Kraft, Andrew

PY - 2015/5/30

Y1 - 2015/5/30

N2 - The initiation and progression of human cancer is frequently linked to the uncontrolled activation of survival kinases. Two such pro-survival kinases that are commonly amplified in cancer are PIM and Akt. These oncogenic proteins are serine/threonine kinases that regulate tumorigenesis by phosphorylating substrates that control the cell cycle, cellular metabolism, proliferation, and survival. Growing evidence suggests that cross-talk exists between the PIM and Akt kinases, indicating that they control partially overlapping survival signaling pathways that are critical to the initiation, progression, and metastatic spread of many types of cancer. The PI3K/Akt signaling pathway is activated in many human tumors, and it is well established as a promising anticancer target. Likewise, based on the role of PIM kinases in normal and tumor tissues, it is clear that this family of kinases represents an interesting target for anticancer therapy. Pharmacological inhibition of PIM has the potential to significantly influence the efficacy of standard and targeted therapies. This review focuses on the regulation of PIM kinases, their role in tumorigenesis, and the biological impact of their interaction with the Akt signaling pathway on the efficacy of cancer therapy.

AB - The initiation and progression of human cancer is frequently linked to the uncontrolled activation of survival kinases. Two such pro-survival kinases that are commonly amplified in cancer are PIM and Akt. These oncogenic proteins are serine/threonine kinases that regulate tumorigenesis by phosphorylating substrates that control the cell cycle, cellular metabolism, proliferation, and survival. Growing evidence suggests that cross-talk exists between the PIM and Akt kinases, indicating that they control partially overlapping survival signaling pathways that are critical to the initiation, progression, and metastatic spread of many types of cancer. The PI3K/Akt signaling pathway is activated in many human tumors, and it is well established as a promising anticancer target. Likewise, based on the role of PIM kinases in normal and tumor tissues, it is clear that this family of kinases represents an interesting target for anticancer therapy. Pharmacological inhibition of PIM has the potential to significantly influence the efficacy of standard and targeted therapies. This review focuses on the regulation of PIM kinases, their role in tumorigenesis, and the biological impact of their interaction with the Akt signaling pathway on the efficacy of cancer therapy.

KW - Akt

KW - Cancer

KW - Oncogenes

KW - PIM kinases

KW - Therapeutic resistance

UR - http://www.scopus.com/inward/record.url?scp=84930087907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930087907&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2015.03.001

DO - 10.1016/j.pharmthera.2015.03.001

M3 - Article

C2 - 25749412

AN - SCOPUS:84930087907

VL - 151

SP - 41

EP - 49

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

ER -